Medizinische Universität Graz - Research portal
Selected Publication:
Zink, M; Gombotz, H; Wasler, A; Grasser, B; Rehak, P; Metzler, H.
Urapidil reduces elevated pulmonary vascular resistance in patients before heart transplantation.
J Heart Lung Transplant. 2002; 21(3):347-353
Doi: 10.1016/S1053-2498(01)00381-3
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-authors Med Uni Graz
- Metzler Helfried
- Rehak Peter
- Wasler Andrae
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Elevated pulmonary vascular resistance is a major limitation for heart transplantation. Urapidil is a centrally and peripherally acting anti-hypertensive drug, able to decrease elevated pulmonary vascular resistance in patients with either chronic obstructive pulmonary disease or heart failure. Urapidil is available as an oral or intravenous drug. In this study, we evaluated the possible beneficial effects of intravenous urapidil in patients with reversible, elevated pulmonary vascular resistance who were scheduled for heart transplantation. METHODS: After approval by the Ethics Committee and written consent, 22 consecutive patients with end-stage heart failure and history of pulmonary vascular resistance >3 Wood units were enrolled into an open, prospective study. Using a (right ventricular ejection fraction) REF-Swan-Ganz catheter, hemodynamics were determined during administration of nitric oxide, and before and after 3 repeated intravenous applications of 10 mg urapidil. The treatment goal was reduction of pulmonary vascular resistance by at least 30%. RESULTS: Twenty-two patients were included to obtain complete data for 14 patients. Eight patients were not treated with urapidil: 7 patients had normal pulmonary vascular resistance at baseline, and 1 patient experienced moderate pulmonary edema before the study began. Two patients did not reach the treatment goal. In patients who responded to urapidil, the following hemodynamic changes were observed: decreased pulmonary vascular resistance (-48%), decreased transpulmonary gradient (20.0 to 13.7 mm Hg), decreased mean pulmonary arterial pressure (40 to 31 mm Hg), decreased systemic vascular resistance (-27%), mean arterial pressure (80 to 72 mm Hg), and increased right heart ejection fraction (21% to 27%). Heart rate remained unchanged. CONCLUSIONS: Intravenous urapidil lowered elevated pulmonary vascular resistance in patients before heart transplantation. In comparison with other vasodilative drugs, the major benefit of urapidil is its oral formulation.
- Find related publications in this database (using NLM MeSH Indexing)
- Antihypertensive Agents - administration and dosage
- Female - administration and dosage
- Heart Transplantation - physiology
- Hemodynamics - drug effects
- Humans - drug effects
- Infusions, Intravenous - drug effects
- Male - drug effects
- Middle Aged - drug effects
- Piperazines - administration and dosage
- Pulmonary Circulation - drug effects
- Vascular Resistance - drug effects
- Vasodilator Agents - administration and dosage